James Cavet
Manchester, ENG M204BX, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Journal: Cancer cell
Published: July 08, 2022
Cancer and climate change: the environmental impact of cancer care.
Journal: The Lancet. Oncology
Published: November 26, 2020
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
Journal: British journal of haematology
Published: July 17, 2020
Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma.
Journal: Bone marrow transplantation
Published: July 24, 2019
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Journal: British journal of haematology
Published: December 01, 2014
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
Journal: The Lancet. Oncology
Published: July 22, 2014
Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial.
Journal: British journal of haematology
Published: September 17, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026